




PHARMACEUTICAL 2022

Cell Source Inc.
Rank 454 of 466





PHARMACEUTICAL 2022

Cell Source Inc.
Rank 454 of 466

The relative strengths and weaknesses of Cell Source Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Cell Source Inc. compared to the market average is the variable Liabilities, Current, increasing the Economic Capital Ratio by 399% points. The greatest weakness of Cell Source Inc. is the variable Assets, Current, reducing the Economic Capital Ratio by 277% points.

The company's Economic Capital Ratio, given in the ranking table, is -428%, being 506% points below the market average of 78%.

Input Variable	Value in 1000 USD
Assets, Current	314
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	10,140
Liabilities, Non-Current	0
Other Assets	0
Other Compr. Net Income	0
Other Expenses	50
Other Liabilities	0
Other Net Income	-1,454
Other Revenues	0
Property and Equipment	0
Research and Development	1,273
Selling, General and Administrative Expense	2,695

Output Variable	Value in 1000 USD
Assets	314
Liabilities	10,140
Expenses	4,019
Revenues	0
Stockholders Equity	-9,826
Net Income	-5,472
Comprehensive Net Income	-5,472
Economic Capital Ratio	-428%